BARDA Will Implement a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Trial in the US to…
FY2024 · complete year · data as of 2026-07-03
A single federal award, with both ends of the trail linked.
Award 75A50124C00001 is a contract from the Department of Health and Human Services, $117.4M obligated, FY2024 to FY2030, for BARDA Will Implement a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Trial in…. The work is performed in North Carolina. It is classified as NAICS 541714 (Research and Development in Biotechnology (except Nanobiotechnology)) and PSC AN12 (Health R&D Services; Health Care Services; Applied Research). Source
Description
BARDA Will Implement a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Trial in the US to Evaluate the Safety and Efficacy of Novel Host-Directed Therapeutic Candidates in Hospitalized Adults with Ards.